BUHLMANN Diagnostic Corp is pleased to announce a new partner channel agreement with Roche Diagnostics for the launch and distribution in the U.S., of the 510(k) cleared automated calprotectin test, BÜHLMANN fCAL^® turbo.

The test, which aides in the diagnosis of inflammatory diseases in the gastrointestinal tract, will be distributed by Roche Diagnostics and used directly on the cobas^® c501/502 chemistry analyzer systems in the US.

The direct application of the fCAL^® turbo on the cobas^® c501/502 analyzers will be a practical and fully automated testing procedure for modern core labs looking for fast and reliable results with little hands-on time. The combination of fCAL^® turbo with the BÜHLMANN CALEX^® Cap extraction device is a significant milestone marking freedom from the cumbersome and laborious manual methods of the past.

For information, please contact your Roche Representative on the c501/502, or BUHLMANN Diagnostic Corp for further details:

Collin - cms@buhlmannlabs.com or 

Jen - jls@buhlmannlabs.com

BÜHLMANN fCAL^® turbo

BUHLMANN DIAGNOSTICS CORP

BUHLMANN Diagnostic Corp, the North American affiliate of BÜHLMANN Laboratories AG, offers the broadest fecal calprotectin (fCAL) product range in the industry to the United States. These fCAL related test include FDA 510(k) cleared BÜHLMANN fCAL^® ELISA, BÜHLMANN fCAL^® turbo & CALEX^® Cap; FDA exempt BÜHLMANN fPELA^® turbo; RUO IBDoc^®, Quantum Blue^® fCAL rapid tests and Quantum Blue^® Infliximab & Adalimumab TDM and Antibody rapid tests. Beyond calprotectin, BDC offers unique assays for Cellular Allergy, Neuroimmunology, Clinical Chemistry and Chronobiology.

Contact Us:

105 Route 101A, Suite 1,
Amherst, NH 03031 USA

Ph: (844) 300-9799
info@buhlmannlabs.com
buhlmannlabs.com